ABVC BioPharma (ABVC)
(Delayed Data from NSDQ)
$1.42 USD
-0.17 (-10.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.45 +0.03 (2.11%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ABVC 1.42 -0.17(-10.69%)
Will ABVC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABVC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ABVC
BACK, ZPTA and ABVC are among premarket gainers
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Tuesday's After-Market Session
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
ABVC BioPharma's AiBtl BioPharma acquires TT Life Company